47
Participants
Start Date
February 28, 2001
Primary Completion Date
January 31, 2007
Study Completion Date
October 31, 2011
fludarabine phosphate
30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
Cyclophosphamide
1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
PBSC
2-8,000,000/kg CD34+ cells via infusion on Day 0
G-CSF
5 ug/kg/day subQ injection until ANC \> 1000/uL for 3 days beginning Day 5
Donor lymphocytes
10,000,000 CD3+ cells/kg via infusion
Mount Sinai Medical Center, New York
Elmhurst Hospital Center, Elmhurst
Queens Cancer Center of Queens Hospital, Jamaica
CCOP - Christiana Care Health Services, Newark
St. Francis Hospital, Wilmington
Beebe Medical Center, Lewes
Union Hospital Cancer Center at Union Hospital, Elkton MD
Holden Comprehensive Cancer Center at University of Iowa, Iowa City
Veterans Affairs Medical Center - San Diego, San Diego
UCSF Comprehensive Cancer Center, San Francisco
Rebecca and John Moores UCSD Cancer Center, La Jolla
UMASS Memorial Cancer Center - University Campus, Worcester
Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees Township
Roswell Park Cancer Institute, Buffalo
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Wake Forest University Comprehensive Cancer Center, Winston-Salem
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh
Massey Cancer Center at Virginia Commonwealth University, Richmond
National Cancer Institute (NCI)
NIH
Cancer and Leukemia Group B
NETWORK